Regenexx Bio said Suravec wet AMD pivotal data are expected this quarter, RGX202’s full BLA filing is planned for the first quarter of 2027, and cash, cash equivalents and marketable securities totaled $251 million at September 30, 2026.
RGNX · REGENXBIO Inc.
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about our ability to continue as a going concern within 12 months from the issuance date of our consolidated financial statements for the three and nine months ended September 30, 2026 included in this Quarterly Report on Form 10-Q.”View the 10-Q filed Nov 5, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 55%
- Last earnings
- Nov 5, 2026
- Latest filing
- 10-Q · Nov 5
- Price history
- Jan 2020 to Nov 2026
Up next
Latest documents
REGENXBIO reported positive pivotal RGX-202 results and plans a BLA submission in the first quarter of 2027, while RGX-121 remains on clinical hold. The wet AMD pivotal program completed enrollment, with topline data expected in the fourth quarter of 2026.
REGENXBIO remains on track to submit the RGX-202 BLA in Q1 2027, while reporting $251.0 million in cash, cash equivalents and marketable securities and a $40.7 million net loss for the third quarter ended September 30, 2026.
Kenneth T. Mills resigned from the board effective October 21, 2026, to focus on his new role as chief executive officer of another company. The board appointed George Migausky as Chairman, and Daniel Tassé stepped down as Lead Independent Director but remains a board member.
On September 23, 2026, REGENXBIO Inc. entered a settlement with Sarepta that requires a $39.0 million payment to REGENXBIO within 10 days of the effective date and terminates all ongoing patent litigation over ELEVIDYS-related patents.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Nov 5, 2026TL;DR. Sura-vec is approaching a Q4 2026 wet AMD data readout, RGX-202 remains on track for a Q1 2027 BLA submission, and available cash is expected to fund operations into late Q4 2027. The main negatives are lower revenue following the ZOLGENSMA patent expiration, higher R&D expenses, cash used in operating activities, and an FDA clinical hold on RGX-121.
- + Sura-vec wet AMD topline data are expected in Q4 2026, with global regulatory submissions expected in 2027.
- + The RGX-202 BLA submission is on track for Q1 2027.
- + Pivotal results showed robust microdistrophin expression, encouraging functional improvement, and a favorable safety profile.
- + At three years, 60% of patients in the ALTITUDE trial improved by at least two steps on the diabetic retinopathy severity scale without additional treatment.
- + Cash, cash equivalents, and marketable securities plus the October settlement proceeds are expected to fund operations into late Q4 2027.
- + The $39.0 million Sarepta settlement payment was received in October 2026, and REGENXBIO recorded a $38.0 million third-quarter gain.
- − Third-quarter revenue fell to $9.2 million from $29.7 million a year earlier.
- − ZOLGENSMA royalty revenue decreased by $21.2 million, primarily because licensed U.S. patents expired in January 2026.
- − Third-quarter R&D expenses increased to $61.0 million from $56.1 million.
- − The FDA placed RGX-121 on clinical hold after asymptomatic spine MRI findings were discovered in five CAMPSIITE participants.
- − Cash used to fund operating activities during the nine months ended September 30, 2026 partially offset the year-to-date increase in cash and marketable securities.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Cash, cash equivalents and marketable securities | $251M | as of September 30, 2026 | — |
| Itvisma royalties | $2.81M | FY2026 Q3 | — |
|
|
|||
| ITVISMA royalty revenues | $2.8M | the third quarter of 2026 | — |
|
|
|||
| Zolgensma royalties | $2.43M | FY2026 Q3 | -89.7% |
|
|
|||
| Interest income from licensing | $10K | Three Months Ended June 30, 2026 filing | — |
| License and royalty revenue under AbbVie Collaboration Agreement | $100M | Three Months Ended June 30, 2026 filing | — |
| Net cost reimbursement to (from) AbbVie included in General and administrative expense | $1.23M | Three Months Ended June 30, 2026 filing | — |
| Net cost reimbursement to (from) AbbVie included in Research and development expense | -$12.05M | Three Months Ended June 30, 2026 filing | — |
| Total net cost reimbursement to (from) AbbVie | -$10.82M | Three Months Ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RGNX
this stock
REGENXBIO Inc.
|
$473.44M | -50.3% | +126.5% | — | 15.4% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$130.58B | +13.6% | +46.2% | 33.2 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.24B | +19.3% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$78.90B | +561.2% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$62.17B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 5, 2026
- This year
- 31
REGENXBIO remains on track to submit the RGX-202 BLA in Q1 2027, while reporting $251.0 million in cash, cash equivalents and marketable securities and a $40.7 million net loss for the third quarter ended September 30, 2026.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RGNX | -6.3% | +7.2% | +9.8% | -0.6% | -50.3% |
| SPY | -8.6% | -9.2% | -9.2% | -8.7% | +1.2% |
| vs SPY | +2.3% | +16.4% | +19.0% | +8.2% | -51.4% |